

Supplementary material

Basophil activation in response to Gelofusine was analyzed by flow cytometry based on CD63 surface expression. The negative control was a stimulation buffer containing heparin, calcium and IL3, and the positive controls included anti-Fc ϵ R1 activating monoclonal antibody and fMLP (Bühlmann Laboratories, Switzerland). The Gelofusine[®] BAT was validated with blood from 5 patients allergic to hymenopteran venom but not allergic to bovine gelatine or alpha-gal. Five concentrations of Gelofusine[®] were tested: 40 g/L; 8 g/L; 4 g/L; 0.4 g/L and 0.08 g/L. Informed consent was obtained from both patients.




Figure S1. Dose-dependent basophil activation (%CD63+ basophils) in patients 1 and 2 determined with allergen solutions for Gelofusine[®] and α -Gal (Bühlman Laboratories, Schönenbuch, Switzerland)